Metformin and cardiorenal outcomes in diabetes : a reappraisal
MetadataShow full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
The guidance issued to the pharmaceutical industry by the US Food and Drug Administration in 2008 has led to the publication of a series of randomised, controlled cardiovascular outcomes trials with newer therapeutic classes of glucose‐lowering medications. Several of these trials, which evaluated the newer therapeutic classes of SGLT2 inhibitors and GLP‐1 receptor agonists have reported a reduced incidence of major adverse cardiovascular and/or renal outcomes, usually relative to placebo and standard of care. Metformin was the first glucose‐lowering agent reported to improve cardiovascular outcomes in the UK Prospective diabetes Study (UKPDS) and thus became the foundation of standard care. However, as this clinical trial reported more than 20 years ago, differences from current standards of trial design and evaluation complicate comparison of the cardiovascular profiles of older and newer agents. Our article revisits the evidence for cardiovascular protection with metformin and reviews its effects on the kidney.
Petrie , J R , Rossing , P R & Campbell , I W 2020 , ' Metformin and cardiorenal outcomes in diabetes : a reappraisal ' , Diabetes, Obesity and Metabolism , vol. Early View . https://doi.org/10.1111/dom.13984
Diabetes, Obesity and Metabolism
Copyright © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.